ad image

European Medicines Agency

1 / 1
Merck & Co.
EMA

European Medicines Agency Adopts Positive Opinion for KEYTRUDA®(pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy

Merck & Co.

PR-M08-18-NI-009Aug 02, 2018
AbbVie
Authorization Application

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

AbbVie

PR-M05-18-NI-016May 04, 2018
1 / 1